Success Metrics

Clinical Success Rate
90.0%

Based on 207 completed trials

Completion Rate
90%(207/230)
Active Trials
95(24%)
Results Posted
17%(36 trials)
Terminated
23(6%)

Phase Distribution

Ph not_applicable
94
23%
Ph phase_2
12
3%
Ph phase_3
6
1%
Ph phase_4
14
3%
Ph phase_1
15
4%
Ph early_phase_1
2
0%

Phase Distribution

17

Early Stage

12

Mid Stage

20

Late Stage

Phase Distribution143 total trials
Early Phase 1First-in-human
2(1.4%)
Phase 1Safety & dosage
15(10.5%)
Phase 2Efficacy & side effects
12(8.4%)
Phase 3Large-scale testing
6(4.2%)
Phase 4Post-market surveillance
14(9.8%)
N/ANon-phased studies
94(65.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.1%

207 of 252 finished

Non-Completion Rate

17.9%

45 ended early

Currently Active

95

trials recruiting

Total Trials

403

all time

Status Distribution
Active(108)
Completed(207)
Terminated(45)
Other(43)

Detailed Status

Completed207
Recruiting71
unknown41
Active, not recruiting24
Terminated23
Withdrawn22

Development Timeline

Analytics

Development Status

Total Trials
403
Active
95
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.4%)
Phase 115 (10.5%)
Phase 212 (8.4%)
Phase 36 (4.2%)
Phase 414 (9.8%)
N/A94 (65.7%)

Trials by Status

withdrawn225%
suspended20%
terminated236%
unknown4110%
enrolling_by_invitation31%
not_yet_recruiting102%
active_not_recruiting246%
recruiting7118%
completed20751%

Recent Activity

Clinical Trials (403)

Showing 20 of 403 trialsScroll for more
NCT04809363Phase 4

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Completed
NCT03403686

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Recruiting
NCT01385176Not Applicable

Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)

Active Not Recruiting
NCT02631720

CLAD Phenotype Specific Risk Factors and Mechanisms

Completed
NCT07270666Not Applicable

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Recruiting
NCT03224949

Comparison of ALD, NASH, and Healthy Control Patients

Recruiting
NCT02711826Phase 1

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed
NCT04088370

Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis

Recruiting
NCT05036707Phase 1

Human Immune Response to Ixodes Scapularis Tick Bites

Recruiting
NCT01920737Phase 2

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT06674811

Biomarkers of Resiliency In Childhood Cancer Surgery

Recruiting
NCT06864819

Role of Phosphatidylethanol in Predicting Perioperative Outcomes of Admitted Patients at UHCMC

Recruiting
NCT07132788

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

Recruiting
NCT07781709Not Applicable

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy

Not Yet Recruiting
NCT06960798

Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

Recruiting
NCT07603869

Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026

Completed
NCT07251179

Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies

Recruiting
NCT05212272Not Applicable

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

Recruiting
NCT05201833

TRACK-TBI Longitudinal Biomarker Study

Active Not Recruiting
NCT03334708

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
403